These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18676347)

  • 21. Berson and Yalow's radioimmunoassay for parathyroid hormone (PTH): a clinical progress report.
    Roof BS; Gordan GS; Goldman L; Piel CF
    Mt Sinai J Med; 1973; 40(3):433-47. PubMed ID: 4351492
    [No Abstract]   [Full Text] [Related]  

  • 22. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
    Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors of hyperparathyroidism in advanced stages of chronic kidney disease.
    El Kossi M; Rana A; El Nahas M
    Saudi J Kidney Dis Transpl; 2009 Jul; 20(4):623-7. PubMed ID: 19587504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Kidney and bone update : the 5-year history and future of CKD-MBD. CKD-MBD and phosphotropic hormones].
    Fukumoto S
    Clin Calcium; 2012 Jul; 22(7):987-91. PubMed ID: 22750930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibroblast growth factor 23 (FGF-23) concentrations in cats with early nonazotemic chronic kidney disease (CKD) and in healthy geriatric cats.
    Finch NC; Geddes RF; Syme HM; Elliott J
    J Vet Intern Med; 2013; 27(2):227-33. PubMed ID: 23363336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biological activity of FGF-23 and pathophysiologic role in chronic kidney disease].
    Yamashita T
    Clin Calcium; 2004 May; 14(5):760-3. PubMed ID: 15577039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast growth factor 23 in feline chronic kidney disease.
    Geddes RF; Finch NC; Elliott J; Syme HM
    J Vet Intern Med; 2013; 27(2):234-41. PubMed ID: 23398216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.
    Gutiérrez OM; Januzzi JL; Isakova T; Laliberte K; Smith K; Collerone G; Sarwar A; Hoffmann U; Coglianese E; Christenson R; Wang TJ; deFilippi C; Wolf M
    Circulation; 2009 May; 119(19):2545-52. PubMed ID: 19414634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical aspect of recent progress in phosphate metabolism. Pathophysiology of secondary hyperparathyroidism in chronic kidney disease].
    Goto S; Fukagawa M
    Clin Calcium; 2009 Jun; 19(6):809-14. PubMed ID: 19483275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications?
    Bielesz B
    Wien Klin Wochenschr; 2010 Apr; 122(7-8):194-7. PubMed ID: 20503017
    [No Abstract]   [Full Text] [Related]  

  • 32. With or without the kidney: the role of FGF23 in CKD.
    Fukagawa M; Kazama JJ
    Nephrol Dial Transplant; 2005 Jul; 20(7):1295-8. PubMed ID: 15840677
    [No Abstract]   [Full Text] [Related]  

  • 33. Metabolic problems in renal transplant patients. Persistent hyperparathyroidism and hypophosphatemia: effects of intravenous calcium infusion.
    Pabico RC; McKenna BA
    Transplant Proc; 1988 Feb; 20(1 Suppl 1):438-42. PubMed ID: 3279634
    [No Abstract]   [Full Text] [Related]  

  • 34. [Delayed measurement of PTH in patients with CKD: storage of the primary tube in the dialysis unit, which temperature? Which kind of tube?].
    Parent X; Alenabi F; Brignon P; Souberbielle JC
    Nephrol Ther; 2009 Feb; 5(1):34-40. PubMed ID: 18674975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Taking aim at targets.
    Palmer SC; Craig JC; Strippoli GF
    Nephrol Dial Transplant; 2009 May; 24(5):1358-61. PubMed ID: 19211650
    [No Abstract]   [Full Text] [Related]  

  • 36. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease.
    Cozzolino M; Ciceri P; Volpi EM; Olivi L; Messa PG
    Blood Purif; 2009; 27(4):338-44. PubMed ID: 19295196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Phosphorus and calcium metabolism and the cardiovascular system status in patients with early-stage chronic renal disease].
    Smirnov AV; Volkov MM; Dobronravov VA; Rafrafi H
    Ter Arkh; 2010; 82(6):25-8. PubMed ID: 20731105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical relevance of FGF-23 in chronic kidney disease.
    Seiler S; Heine GH; Fliser D
    Kidney Int Suppl; 2009 Dec; (114):S34-42. PubMed ID: 19946326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGF-23 and secondary hyperparathyroidism in chronic kidney disease.
    Silver J; Naveh-Many T
    Nat Rev Nephrol; 2013 Nov; 9(11):641-9. PubMed ID: 23877588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?
    Peiskerová M; Kalousová M; Kratochvílová M; Dusilová-Sulková S; Uhrová J; Bandúr S; Malbohan IM; Zima T; Tesar V
    Kidney Blood Press Res; 2009; 32(4):276-83. PubMed ID: 19797911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.